ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Varmus Confirmation On Fast Track, Nominee Outlines Goals For Next Year

November 12, 1993

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

In Brief: Forel Retires As Dana-Farber Director, Successor Is David Livingston; Benacerraf Plans Departure

July 5, 1991

ODAC Recommends Ethyol, DaunoXome For FDA Approval

June 16, 1995

FDA Throws Up IND Roadblock, Then Refuses To Answer Investigator’s Letters About It

February 6, 1976

In Brief: Senate Health Subcommittee Lineup Completed; GAO Calls For More Ionizing Radiation Studies

January 23, 1981